Genomic Predictors of Decitabine Response in AML/MDS

Fecha de inicio: 12 de febrero de 2013

Inclusion Criteria: All of the following: Patient must have non-M3 AML or MDS An adverse risk karyotype defined by: Complex karyotype by cytogenetics, or Deletion of all or part of chromosome 5, 7, 12, or 17 defined by FISH or cytogenetics, or Somatic TP53 mutation All of the following: Patient must have an ECOG performance status ≤ 2. Patient must have >10% disease burden measured by cytomorphology, flow cytometry, or cytogenetics. Patient must have peripheral white blood cell count < 50,000/mcl. Patient must have adequate organ function, defined as: Total bilirubin < 1.5 x ULN AST/ALT < 2.5 x ULN Serum creatinine < 2.0 x ULN Patient must have undergone ≤ 2 cycles of prior hypomethylating agent (decitabine or azacitidine). Patient must be enrolled in HRPO# 201011766 ("Tissue Acquisition for Analysis of Genetic Progression Factors in Hematologic Diseases"). Patient must be > 18 years of age. Patient must be able to understand and willing to sign an IRB-approved written informed consent document. Exclusion Criteria: Patient must not be pregnant or nursing Patient must not have acute promyelocytic leukemia or t(15;17) observed by FISH. Patient must not have known central nervous system (CNS) leukemia Patient must not have a history of positive human immunodeficiency virus (HIV) serology Patient must not have a history of positive hepatitis C serology Patient must not have undergone prior allogeneic stem cell transplant Patient must not have any uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, ongoing or active graft-versus-host disease (GVHD), congestive heart failure of New York Heart Association (NYHA) class 3 or 4, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situation that would limit compliance with study requirements Patient must not have had radiation therapy within 14 days of enrollment Patient must not have received any chemotherapy within 21 days of enrollment and any acute treatment-related toxicities must have returned to baseline. Patients may be receiving hydrea at time of enrollment.